AKT1 and osteosarcoma: Many of these drugs (linsitinib (OSI-906), AKT inhibitor MK-2206, PI3K inhibitor GDC0941, Cyclopamine) have been shown to inhibit the progression of osteosarcoma (Warzecha et al. 2007; Hirai et al. 2010; Kuijjer et al. 2013; Wan et al. 2022), however their studies on the effect of treatment in the high- and low-risk groups based on cellular senescence-associated genes in juvenile osteosarcoma patients remain to be further carried out.